You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser.
Administrator
Staff member
-
cafead   Jan 28, 2025 at 10:42: AM
Administrator
Staff member
via Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial.
article source